Richard J Miron1,2,3, Masako Fujioka-Kobayashi4,5,6, Maria Hernandez4, Umadevi Kandalam7, Yufeng Zhang8, Shahram Ghanaati9, Joseph Choukroun10. 1. Department of Periodontology, College of Dental Medicine, Nova Southeastern University, Fort Lauderdale, FL, USA. rmiron@nova.edu. 2. Cell Therapy Institute, Center for Collaborative Research, Nova Southeastern University, Fort Lauderdale, FL, USA. rmiron@nova.edu. 3. Department of Periodontics and Oral Medicine, University of Michigan, Ann Arbor, MI, USA. rmiron@nova.edu. 4. Department of Periodontology, College of Dental Medicine, Nova Southeastern University, Fort Lauderdale, FL, USA. 5. Department of Cranio-Maxillofacial Surgery, University of Bern, Bern, Switzerland. 6. Department of Oral Surgery, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan. 7. Department of Pediatric Dentistry, College of Dental Medicine, Nova Southeastern University, Fort Lauderdale, FL, USA. 8. Department of Oral Implantology, University of Wuhan, Wuhan, China. 9. FORM, Frankfurt Oral Regenerative Medicine, Clinic for Maxillofacial and Plastic Surgery, Johann Wolfgang Goethe University, Frankfurt Am Main, Germany. 10. Pain Clinic, Nice, France.
Abstract
OBJECTIVES: Platelet rich plasma (PRP) has been utilized in regenerative dentistry as a supra-physiological concentrate of autologous growth factors capable of stimulating tissue regeneration. Despite this, concerns have been expressed regarding the use of anti-coagulants, agents known to inhibit wound healing. In this study, a liquid formulation of platelet rich fibrin (PRF) termed injectable-PRF (i-PRF) without the use of anti-coagulants was investigated. MATERIALS AND METHODS: Standard PRP and i-PRF (centrifuged at 700 rpm (60G) for 3 min) were compared for growth factor release up to 10 days (8 donor samples). Furthermore, fibroblast biocompatibility at 24 h (live/dead assay); migration at 24 h; proliferation at 1, 3, and 5 days, and expression of PDGF, TGF-β, and collagen1 at 3 and 7 days were investigated. RESULTS: Growth factor release demonstrated that in general PRP had higher early release of growth factors whereas i-PRF showed significantly higher levels of total long-term release of PDGF-AA, PDGF-AB, EGF, and IGF-1 after 10 days. PRP showed higher levels of TGF-β1 and VEGF at 10 days. While both formulations exhibited high biocompatibility and higher fibroblast migration and proliferation when compared to control tissue-culture plastic, i-PRF induced significantly highest migration whereas PRP demonstrated significantly highest cellular proliferation. Furthermore, i-PRF showed significantly highest mRNA levels of TGF-β at 7 days, PDGF at 3 days, and collagen1 expression at both 3 and 7 days when compared to PRP. CONCLUSIONS: i-PRF demonstrated the ability to release higher concentrations of various growth factors and induced higher fibroblast migration and expression of PDGF, TGF-β, and collagen1. Future animal research is now necessary to further validate the use of i-PRF as a bioactive agent capable of stimulating tissue regeneration. CLINICAL RELEVANCE: The findings from the present study demonstrate that a potent formulation of liquid platelet concentrates could be obtained without use of anti-coagulants.
OBJECTIVES: Platelet rich plasma (PRP) has been utilized in regenerative dentistry as a supra-physiological concentrate of autologous growth factors capable of stimulating tissue regeneration. Despite this, concerns have been expressed regarding the use of anti-coagulants, agents known to inhibit wound healing. In this study, a liquid formulation of platelet rich fibrin (PRF) termed injectable-PRF (i-PRF) without the use of anti-coagulants was investigated. MATERIALS AND METHODS: Standard PRP and i-PRF (centrifuged at 700 rpm (60G) for 3 min) were compared for growth factor release up to 10 days (8 donor samples). Furthermore, fibroblast biocompatibility at 24 h (live/dead assay); migration at 24 h; proliferation at 1, 3, and 5 days, and expression of PDGF, TGF-β, and collagen1 at 3 and 7 days were investigated. RESULTS: Growth factor release demonstrated that in general PRP had higher early release of growth factors whereas i-PRF showed significantly higher levels of total long-term release of PDGF-AA, PDGF-AB, EGF, and IGF-1 after 10 days. PRP showed higher levels of TGF-β1 and VEGF at 10 days. While both formulations exhibited high biocompatibility and higher fibroblast migration and proliferation when compared to control tissue-culture plastic, i-PRF induced significantly highest migration whereas PRP demonstrated significantly highest cellular proliferation. Furthermore, i-PRF showed significantly highest mRNA levels of TGF-β at 7 days, PDGF at 3 days, and collagen1 expression at both 3 and 7 days when compared to PRP. CONCLUSIONS: i-PRF demonstrated the ability to release higher concentrations of various growth factors and induced higher fibroblast migration and expression of PDGF, TGF-β, and collagen1. Future animal research is now necessary to further validate the use of i-PRF as a bioactive agent capable of stimulating tissue regeneration. CLINICAL RELEVANCE: The findings from the present study demonstrate that a potent formulation of liquid platelet concentrates could be obtained without use of anti-coagulants.
Authors: R E Marx; E R Carlson; R M Eichstaedt; S R Schimmele; J E Strauss; K R Georgeff Journal: Oral Surg Oral Med Oral Pathol Oral Radiol Endod Date: 1998-06
Authors: Francesca Salamanna; Francesca Veronesi; Melania Maglio; Elena Della Bella; Maria Sartori; Milena Fini Journal: Biomed Res Int Date: 2015-05-05 Impact factor: 3.411
Authors: Simon Wend; Alica Kubesch; Anna Orlowska; Sarah Al-Maawi; Niklas Zender; Andre Dias; Richard J Miron; Robert Sader; Patrick Booms; C James Kirkpatrick; Joseph Choukroun; Shahram Ghanaati Journal: J Mater Sci Mater Med Date: 2017-10-25 Impact factor: 3.896